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Abstract
The main aim of this section is to provide clinicians with a guide to the prevalence of psy-
chopathologies, associated factors, and their treatment in children with Down syndrome 
(DS). Attention-deficit/hyperactivity disorder (ADHD), behavioral disorders, depression, 
and autism are more common in DS than the normal population. However, the incidence 
of psychopathology is generally lower in DS than in other diseases that cause mental 
retardation. While writing this chapter, approximately 200 articles in electronic databases 
were scanned using the keywords “Down Syndrome and Psychopathology,” “Down 
Syndrome and Mood Disorder,” “Down Syndrome and Autism,” “Down Syndrome 
and Anxiety,” “Down Syndrome and Catatonia,” and “Down Syndrome and Behavioral 
Disorder.” Psychopathologies in DS will be presented in eight subtitles beginning with 
the most often diagnosed. It is important to perform psychological evaluations of patients 
with DS during routine follow-ups. Comorbid diseases (obstructive sleep apnea, cardiac 
pathologies, etc.) should be taken into account when choosing drugs.
Keywords: down syndrome, psychopathology, mental health
1. Introduction
Down syndrome (DS) is the most common chromosomal anomaly which is associated with 
intellectual disability (ID), typical physical features, and health problems. The incidence of 
DS is about 1–1.5 of every 1000 live births. DS is the most frequent genetic cause of mental 
retardation (MR) [1]. People with MR have behavioral, emotional, and psychiatric problems 
more often than the general population [2].
DS exhibits distinctive neurodevelopmental, neurocognitive, and psychopathological patterns 
when compared to other genetic syndromes leading to ID, albeit higher than the general popula-
tion [3]. A 28.9% of the children with DS have psychiatric comorbidity [4]. The children with DS 
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are more likely to have externalizing behaviors than their siblings and peers, including hyper-
activity, impulsivity, inattention, tantrums, agitation, stubbornness, disruptiveness/argumenta-
tiveness, oppositionality, repetitive movements, sensory dysregulation, and speech problems 
despite being recognized as friendly, easygoing, good tempered, affectionate, and sympathetic 
individuals [3, 5, 6]. The rate of severe behavior disorder in children with DS is reported as 23% 
[7]. The 4- to 18-year-old children with DS are more likely to exhibit such externalizing behav-
iors compared to normal-developing controls; 6–8% of children with DS are diagnosed with 
attention-deficit/hyperactivity disorder (ADHD); and 10–15% of children or youth are diag-
nosed with behavioral or oppositional disorders [2]. Externalizing behaviors change into inter-
nalizing behaviors in adolescents with DS. Internalizing behavior problems such as withdrawal, 
shyness, low confidence, and depression are more common in adolescents and adults [2]. A lon-
gitudinal cohort study showed that the incidence of depressive disorders was 5.2% of the total 
sample of adolescents and adults (16 years) with DS [8]. Depressive symptoms can also be seen 
with increased maladaptive behaviors other than known symptoms deteriorating speech and 
adaptive skills and fluctuating motor symptoms. As in the general population, anxiety symp-
toms such as fear, trembling, flushing, and irritability can be observed in DS [9]. However, there 
is not enough data on the incidence and prevalence of anxiety symptoms in DS. Some have 
shown that the prevalence of obsessive-compulsive disorder (OCD) in DS ranges from 0.8 to 
4.5% and not much higher than the general population. These rates may be low because it is 
difficult to assess the obsessions and compulsions in individuals with cognitive impairment. 
As for OCD, there is a lower prevalence of schizophrenia and bipolar disorder in individuals 
with DS [3]. In latest studies, the co-occurrence of DS and autism spectrum disorders (ASD) has 
increased ratio; approximately 6–10% of children have comorbid ASD [5]. Compared with the 
children with ASD in general, the children with DS are diagnosed with ASD in 6–16 years of age. 
The syndrome that may overlap with DS phenotypic social communication patterns may be dif-
ficult to define in the DS population due to behavioral diagnostic criteria [10].
The prevalence of DS was 5.9 per 10,000 general population. Point prevalence of mental disor-
der of any type varied from 23.7 to 10.8%; 2-year incidence varied from 14.9 to 3.7% [8]. This 
suggests that psychopathology is not seen in a minor proportion of individuals with DS. In 
this article, we aimed to define psychopathology in individuals with DS and to guide the clini-
cians in diagnosis and treatment.
2. Attention-deficit/hyperactivity disorder (ADHD)
ADHD is a developmental disorder with a prevalence of 5% in the community [11]. ADHD 
frequency in DS is 14–43.9% [12, 13].
It was thought that attention deficit and hyperactivity are caused by maturation retardation 
in the past years, and therefore there should not be an additional diagnosis other than men-
tal retardation [14]. Diagnostic overshadowing has been used to describe this situation [15]. 
However, according to both the Diagnostic and Statistical Manual of Mental Disorders-IV 
(DSM-IV) and the DSM-V, mental retardation is not an exclusion criterion for ADHD [16, 17].
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ADHD has three main symptoms: inattention, impulsivity, and hyperactivity, which are 
disproportionate to mental age. These symptoms can be observed in children with DS, but 
impulsivity and hyperactivity are more prominent up to 36 months [18]. In a study in 14 DS 
children (aged 2–4 years), ADHD was diagnosed in 30% of the children [19].
The children with DS may have mental retardation in mild (IQ 50–70), moderate (IQ 35–50), or 
severe (IQ 20–35) levels [20]. Studies of whether there is a correlation between the symptoms 
of ADHD and the degree of mental retardation are contradictory [12, 19, 21, 22]. It is known 
that executive functions are inadequate in ADHD. DS is also known to be inadequate in exec-
utive functions (especially in process memory) [23, 24]. Visual and hearing loss, obstructive 
sleep apnea, and thyroid disease associated with DS may mimic symptoms of ADHD [12].
The most commonly used drugs in the treatment of ADHD are psychostimulants and atom-
oxetine. Psychostimulants are the first line of treatment [25–28]. However, cardiac pathology 
in 50% of DS patients lead to the preference of other drug groups such as alpha-adrenergic 
agonists in place of methylphenidate in the treatment of ADHD [29, 30]. In addition, the pres-
ence of decreased dopamine beta-hydroxylase and increased catechol-o-methyltransferase 
activity in DS also modifies methylphenidate efficacy [31]. In support of this view, the only 
study of ADHD treatment in DS was performed using guanfacine. Twenty-three children 
aged between 4 and 12 years were included in the study and given guanfacine treatment. The 
effect size of guanfacine for inattention was found to be 0.7, and the effect size for hyperactiv-
ity was found to be 0.9; no serious side effects were reported [18]. Thus, there is a need for 
more research for the treatment of ADHD in DS.
3. Conduct disorder
Conduct disorder as other psychopathologies is more common in children with mental retardation 
[32]. More than 10% of the children with DS were diagnosed with conduct disorder [33]. Conduct 
disorder prevalence in DS is lower than other pathologies causing mental retardation [34].
Externalizing behaviors in DS is more common than internalizing behavior [35]. In a study, 
which used the Child Behavior Checklist and included 211 children with DS, stubbornness 
(79%) and disobedience (74%) were reported. Stubbornness has been reported to be a char-
acteristic of DS. In the same study, behavioral problems peaked between 10 and 13 years of 
age, and in accordance with clinical practice, externalizing behavior was reduced toward late 
adolescence and internalizing behavior was increased. However, in both adult and pediatric 
samples, it has been found that fighting (12%) and excessive physical aggression (6%) in indi-
viduals with DS are rare [36].
Some atypical antipsychotics approved by the Food and Drug Administration (FDA) for the 
treatment of aggression in autism are often used off-label in the treatment of aggression in 
patients with mental retardation [37]. Studies have shown that the use of atypical antipsy-
chotics in DS peaked between 11 and 14 years of age. This age range is also the period when 
behavior problems are frequently seen in DS. Behavioral problems in DS are more common in 
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males than in females, and consistent with this, atypical antipsychotic use is more common in 
males [28, 36]. Thus, there is a need for new studies, especially on drug treatment.
4. Depression
The prevalence of psychopathology is higher in DS than healthy population [34]. However, 
psychopathology is less frequent in DS compared to other children with intellectual disability 
[3]. The prevalence of depression in DS is 11%; DS is also a risk factor for developing depression 
[38, 39]. Depression frequency is lower in children and adolescents with DS than adults [40].
Stress-related disorders, such as depression, are the result of complex interactions of exter-
nal stressors and biological factors [41]. Cognitive impairment and inadequacy of problem-
solving skills lead to social rejection and failure [42]. In DS, the total brain volume and 
hippocampus volume are smaller than the normal population, leading to an increased risk of 
depression [43, 44]. These structural changes in the brain are thought to be caused by a protein 
overexpression encoded on chromosome 21 [45]. It is thought that serotonin, an important 
neurotransmitter in brain development, is deficient in fetal life in individuals with DS and 
that this deficiency continues in adulthood and increases susceptibility to depression [46].
Diagnosing depression is difficult in children with DS due to various problems related to 
neurophysiological developments (retardation in nonverbal communication, delay in speech) 
[28]. The most common symptom of depression in DS is the loss of interest (95.4%). In addi-
tion, changes in sleep and appetite patterns (81.8%), agitation (72%), and anxiety (40.9%) are 
other common symptoms [47]. Suicidal thoughts and guilt are rare [48].
In a study, only half of the 56 patients with DS who were diagnosed with depression were 
found to meet the criteria for major depression according to the Diagnostic and Statistical 
Manual of Mental Disorders. This is thought to be due to the lack of separate diagnostic crite-
ria for patients with mental retardation [49].
Depression in people with DS needs to be separated from hypothyroidism, because hypothy-
roidism is more common among people with DS than the normal population [50]. In addition, 
sleep apnea, which may mimic depression, may be diagnosed at a rate of 30–60% in DS [39, 51].
The most commonly used drug is selective serotonin reuptake inhibitors (SSRI), but there is 
no controlled study in this respect [52]. In a retrospective study involving 832 children and 
adolescents with DS, the rate of SSRI use was 9.6% for 5- to 11-year olds and 7.6% for 12- to 
21-year olds [28]. In a study compiling case reports, antidepressant treatment response rate 
was found to be 50% [49]. In addition, electroconvulsive therapy and psychotherapies can be 
used in therapy [53–55].
5. Autism
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
restricted, repetitive behavior and interests and difficulties in social communication and 
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social interaction. The prevalence of autism in the world is about 1%, and approximately 45% 
of the cases are accompanied by intellectual disability. About 5–39% of ASD individuals have 
DS and 1–11% of DS individuals have ASD. Autism is more common among individuals with 
DS than the general population [56, 57].
ASD was reported in other chromosome abnormalities (21–50% of affected individuals have 
autism in fragile X syndrome, 24–60% in tuberous sclerosis complex, 50–81% in Angelman 
syndrome, 60–70% in Timothy syndrome, ~40% in Joubert syndrome, 5–20% in phenylketon-
uria, and 15–50% in CHARGE syndrome). DS is a chromosomal anomaly characterized by 
trisomy 21. Overlapping or co-occurrence of DS and ASD mechanisms is uncertain. Obstetric 
difficulties and/or fetal maldevelopment, congenital or early-acquired brain defects, vulner-
ability to anoxia, infection, or other harmful effects during the intrauterine or neonatal period 
as a result of chromosome abnormalities are some of the etiological factors suggested for DS 
and ASD in literature. Hereditary factors, epilepsy, and hypothyroidism are other medical 
conditions likely to cause autism in DS [13, 56, 58].
Meta-analyses and postmortem studies suggest that both autism and DS have neuropatho-
logical features in cerebellar and cerebral cortices such as heterotopic areas or focal abnormal 
gray matter density differences (amygdala, hippocampus, temporal lobe, cerebellum). These 
neuroanatomical differences, although not specific to autism and DS, may reflect changing 
functional organization patterns that are common to both [3, 56]. Cerebellum and brainstem 
white matters have increased volumes in individuals with autism along with DS in compari-
son to those without autism. These areas associated with stereotypes [59].
The children with DS are diagnosed with ASD in 6–16 years of age compared to the children 
with ASD only. The disorder, which may overlap with the phenotypic social communication 
patterns of DS, may be difficult to define in the DS population because the behavioral diag-
nostic criteria and regression occur later; an onset between 3 and 8 years of age may also be a 
reason for the delay in diagnosis [10, 57].
DS individuals without autism are communicated and socially motivated despite their verbal 
disabilities and show more advanced interpersonal relationships and play and leisure time 
skills than children with ASD. The evidence of autism are impairment of communicative ges-
ture, mime, and facial expression; impairment in the ability to initiate or sustain conversation; 
social reciprocity; lack of eye contact; poor social orienting; infrequent social overtures; poor 
integration of verbal and nonverbal behaviors; lack of joint attention; restricted shared effect; 
inconsistent social responding (tendency to be alone, difficulty in interacting with children); 
constrained imitation; failure to develop functional means of communication; delayed speech 
(although motor milestones such as sitting and walking without support are within normal 
limits); habit of making irrelevant remarks; repeating the other person’s phrases; echolalia; 
dull and repetitive play (such as rolling a toy over and over again); repetitive movements 
(such as frequent tapping of feet, flapping of arms, constant rocking of the body, compulsive 
touching of people, indiscriminate habit of feeling the texture of objects); undue attachment 
to certain objects; and distress over changes in environment [60, 61]. All these evidence are 
might also be seen DS individuals with autism. Individuals with DS alone may show lan-
guage stereotypes, specific interests in parts of objects, rituals, specific body use, and strange 
behavioral patterns specific to DS. ASD in DS is diagnosed with specific autistic features that 
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include phenotypic behavioral features which may be determined by through and widely 
used screening tools (ADOS, CARS, M-CHAT) and DSM-V criteria [57].
The treatment and monitoring program should be structured according to the functional level 
and the disability areas of the affected person because each individual with DS has problems 
at different levels. Treatment approaches in ASD can be grouped into two categories as “edu-
cational treatments” and “pharmacological treatments.”
There is no medical agent for treating the core symptoms of autism. But antipsychotic drugs 
(haloperidol, risperidone, aripiprazole) have been shown to effectively reduce challenging, 
stereotypic behaviors, irritability, tantrum, and hyperactivity. Educational approaches are the 
most effective approach to alleviate basic symptoms and increase functioning in autism [62, 63].
Early diagnosis of ASD in DS is important so that convenient educational, behavioral, rehabil-
itative, and therapeutic interventions and strategies are available to help ensure that children 
receive the best possible outcomes.
6. Obsessive-compulsive disorder (OCD)
Obsessive-compulsive disorder (OCD) is characterized by the presence of obsessions and 
compulsions. Obsessions are thought, impulse, and dreams in which attempts to disengage, 
if accepted as repetitive, disturbing, and illogical, have failed. Compulsions are repetitive 
behaviors and mental actions that appear to reduce obsessions and reduce anxiety caused by 
obsessions. OCD was classified with DSM-5 under the heading “Obsessive-Compulsive and 
Related Disorders” by subtracting it from the heading of “Anxiety Disorders” [64].
The prevalence of OCD in a follow-up study was reported as 3.5% [65], and other studies have 
shown that the prevalence of OCD among individuals with DS ranges from 0.8 to 4.5% and 
not much higher than the general population. These rates may be low because it is difficult 
to assess the obsessions and compulsions in individuals with cognitive impairment. OCD 
increases similar to depression and other internalizing behavior problems among adolescents 
and adults with DS.
The individuals with DS present with ordering and tidiness compulsions, which are the most 
commonly reported OCD symptoms. On the other hand “obsessional slowness” is described as 
a ritualistic behavior that is the part of compulsion in individuals with DS. In case reports, OCD 
symptoms such as compulsively turning off lights, insisting that all doors needed to be shut, 
aligning the objects like books and pictures, hoarding behaviors such as keeping objects (water 
bottles, sunglasses, and boxes), touching rituals (touching the floor in a ritualistic manner sev-
eral times, touching each of clothes hangers routinely each morning), fastidiousness, spend 
excessive amounts of time in the bathroom, taking too long to complete daily routine (slowness 
in daily living skills, eating, and walking), perfectionism, and checking were reported.
The first line of pharmacological treatment for OCD includes SSRIs. Switching to another SSRI, 
augmentation with neuroleptics and the use of a serotonin norepinephrine agent are sug-
gested as pharmacological treatment options for treatment-resistant OCD [66]. In literature, 
Advances in Research on Down Syndrome22
it was shown that SSRIs were effective with OCD in DS, and neuroleptic augmentation was 
effective with treatment-resistant OCD in DS. Also, recent studies suggest that glutamatergic 
agents such as memantine are effective in treatment-resistant OCD in both individuals with 
or without DS [67].
7. Anxiety disorders
Fear and anxiety are necessary to survive by resisting danger and threat. Although it is an 
adaptive process, fear and anxiety may become pathological when they are incited by objects 
or situations that are not legitimately harmful or threatening and restrict the person’s func-
tioning [68]. Anxiety disorders include specific phobias, separation anxiety disorder, selective 
mutism, social anxiety disorder (social phobia), generalized anxiety disorder, panic disor-
der, panic attack specifier and agoraphobia, substance-/medication-induced anxiety disorder, 
anxiety disorder due to another medical condition, other specified anxiety disorders, and 
unspecified anxiety disorder [16].
DS exhibits distinctive neurodevelopmental, neurocognitive, and psychopathological pat-
terns when compared to other genetic syndromes leading to ID, albeit higher than the gen-
eral population [3]. People with ID often have more behavioral, emotional, and psychiatric 
problems than the general population [2]. Anxiety disorder is one of these psychiatric prob-
lems. Studies suggest that 10–22% of the individuals with ID have met diagnostic criteria for 
anxiety disorder; this rate is higher than the individuals with typical development (3–7%). 
Studies have found no difference in prevalence of anxiety among mentally disabled individu-
als between the genders [69]. As in the general population, anxiety symptoms such as fear, 
trembling, flushing, and irritability can be observed in DS [9]. However, there is no enough 
data on the incidence and prevalence of anxiety symptoms in DS.
Children with DS are more common to have externalizing behaviors than their siblings and 
peers despite being recognized as friendly, easygoing, good tempered, affectionate, and 
sympathetic individuals; these behaviors include hyperactivity, impulsivity, inattention, tan-
trums, agitation, stubbornness, disruptiveness/argumentativeness, oppositionality, repeti-
tive movements, sensory dysregulation, and speech problems [3, 5, 6]. ADHD and anxiety 
comorbidities were found higher among individuals with DS-ID than in typically developed 
individuals [3, 69].
Treatment of anxiety disorders in childhood contains psychotherapeutic and psychopharma-
cological interventions, specifically cognitive behavioral therapy (CBT), behavioral therapy, 
and SSRIs. However, there is no enough study in literature for anxiety in DS and treatment of 
anxiety in DS [68]. There is a need for more studies on this subject.
8. Bipolar disorder
There is no study on the prevalence of bipolar disorder in children and adolescents, but the 
prevalence of bipolar disorder is 1% in life. Interestingly, it was found to be 0.3% in DS. This 
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rate is 1.6% in other disorders causing mental retardation. Bipolar disorder in DS is less com-
mon than the normal population, leading to the hypothesis that the susceptibility to bipolar 
disorder may be on chromosome 21. Recent studies have also shown that the susceptibility to 
bipolar disorder is in the 21q22 locus, which expresses the protein that regulates intracellular 
calcium concentration [70, 71]. Thus, individuals with DS with an extra chromosome 21 can 
compensate for the potential effects of the chromosome 21 with the disease [72].
9. Catatonia
Catatonia is a neuropsychiatric syndrome with typical motor indications and responds to 
electroconvulsive therapy and benzodiazepines [73]. The main signs are changes in motor 
activity, movement disorders (stereotype, grimas, and tics), changes in speech, impairment of 
oral intake, negativism, and urinary and gaita incontinence [74]. Neurological, autoimmune, 
and infectious causes must be excluded before the diagnosis of catatonia [75].
The prevalence of catatonia among children and adolescents with DS is not fully known, but 
case reports are available in the literature. In four case reports published in 2015, patients 
who were diagnosed with catatonia and did not respond to benzodiazepine treatment were 
treated with electroconvulsive therapy [48, 75].
The clinician should examine catatonia when regression—sudden loss of good acquired 
skills—is present. A significant number of adolescents with DS experience regression. In 
such a case, comprehensive psychiatric and physical examination is required for diagnosis. 
Physical examination is especially important for the exclusion of autoimmune and neuro-
logical diseases. A dramatic response to 1–2 mg lorazepam administration is a typical sign 
in catatonia. Symptoms such as mood swings, loss of interest and desire, and sleep and 
appetite disorders that can be seen in mood disorders can also be seen in the catatonia. 
The motor symptoms seen in the catatonia and the inability to respond to antidepressant 
and mood stabilizers in treatment are used in differential diagnosis. Individuals with DS 
generally do not respond to benzodiazepine therapy and require electroconvulsive therapy 
[27, 75, 76].
In conclusion, studies suggest that children with DS are at increased risk of having psycho-
pathologies. The clinicians should not neglect the psychopathology in DS and must direct DS 
individuals to psychiatric examination and treatment. Nevertheless, there is a need for further 
studies about DS and psychopathology.
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